West Pharmaceutical Services EPS (Diluted) increased by 5.5% to $1.92 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 56.1%, from $1.23 to $1.92. Over 4 years (FY 2021 to FY 2025), EPS (Diluted) shows a downward trend with a -5.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher values indicate stronger profitability even when accounting for potential share dilution.
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Used by all public companies to provide a realistic view of earnings per share for investors.
eps_diluted| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.47 | $2.31 | $1.89 | $2.29 | $2.48 | $1.59 | $1.37 | $1.85 | $2.06 | $2.14 | $1.83 | $1.55 | $1.51 | $1.85 | $1.78 | $1.23 | $1.82 | $1.92 | $1.82 | $1.92 |
| QoQ Change | — | -6.5% | -18.2% | +21.2% | +8.3% | -35.9% | -13.8% | +35.0% | +11.4% | +3.9% | -14.5% | -15.3% | -2.6% | +22.5% | -3.8% | -30.9% | +48.0% | +5.5% | -5.2% | +5.5% |
| YoY Change | — | — | — | — | +0.4% | -31.2% | -27.5% | -19.2% | -16.9% | +34.6% | +33.6% | -16.2% | -26.7% | -13.6% | -2.7% | -20.6% | +20.5% | +3.8% | +2.2% | +56.1% |